Human N-acetylation genotype determination with urinary caffeine metabolites

Kilbane, Anthony J; Silbart, Lawrence K.; Manis, M; Beitins, Inese Z.; Weber, Wendell W.

doi:10.1038/clpt.1990.59

Cited by 39 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The proportions of rapid and slow acetylators vary remarkably between populations of different ethnic and/or geographic origin (Sabbagh et al, 2011;Walker et al, 2009;Weber and Hein, 1985). Depending on the test substrate administered, a trimodal, rather than bimodal, distribution can be observed, revealing an additional, intermediate phenotype (Cascorbi et al, 1995;Kilbane et al, 1990;Parkin et al, 1997).…”

Section: Introductionmentioning

confidence: 99%

A Homogenizing Process of Selection Has Maintained an “Ultra-Slow” Acetylation <em>NAT2</em> Variant in Humans

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

A Homogenizing Process of Selection Has Maintained an “Ultra-Slow” Acetylation <em>NAT2</em> Variant in Humans

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The first step in the metabolic activation pathway involves N-oxidation by P450 enzymes in the liver followed by additional metabolism by N-acetyltransferase-2 and sulfotransferases (SULT). The N-acetyltransferase-2 enzyme is coded by a single gene displaying two phenotypes, slow and rapid acetylators (41). Similarly, a functional polymorphism in the gene coding for the SULT1A1 enzyme (within the SULTs family) generates a protein with decreased enzyme activity (42).…”

mentioning

confidence: 99%

Meat Consumption among Black and White Men and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort

Rodríguez

McCullough

Mondul

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

111

View full text Add to dashboard Cite

Previous epidemiologic studies have suggested that intake of red meat may be associated with increased risk of prostate cancer. Few studies, however, have examined these associations by race. We examined intake of red meat, processed meat, and poultry in relation to incident prostate cancer among Black and White men in the Cancer Prevention Study II Nutrition Cohort. Participants in the study completed a detailed questionnaire on diet, medical history, and lifestyle in 1992 to 1993. After excluding men with a history of cancer and incomplete dietary information, 692 Black and 64,856 White men were included in the cohort. During follow-up through August 31, 2001, we documented 85 and 5,028 cases of incident prostate cancer among Black and White men, respectively. Cox proportional hazards models were used to estimate rate ratios (RR) and 95% confidence intervals (95% CI). No measure of meat consumption was associated with risk of prostate cancer among White men. Among Black men, total red meat intake (processed plus unprocessed red meat) was associated with higher risk of prostate cancer (RR, 2.0; 95% CI, 1.0-4.2 for highest versus lowest quartile; P trend = 0.05); this increase in risk was mainly due to risk associated with consumption of cooked processed meats (sausages, bacon, and hot dogs; RR, 2.7; 95% CI, 1.3-5.3 for highest versus lowest quartile; P trend = 0.008). This study suggests that high consumption of cooked processed meats may contribute to prostate cancer risk among Black men in the United States. (Cancer Epidemiol Biomarkers Prev 2006; 15(2):211 -6)

show abstract

“…Chez les acétyleurs rapides, on peut craindre un risque accru d'échecs thérapeutiques mais surtout un risque plus important d'hépatotoxicité liée à la surproduction d'un métabolite hépatotoxique de l'isoniazide qui est l'acétylhydra-zyl [25]. Il a également été décrit un phénotype d'acétyleurs intermédiaires de la NAT2 classant ainsi les sujets en trois populations différentes selon le profil d'acétylation [7,26].…”

Section: Introductionunclassified

“…C'est une substance ubiquitaire et relativement non toxique même à fortes doses, métabolisée par la voie de la N-acétylation et recommandée comme marqueur pour la détermination du phé-notype d'acétylation par plusieurs auteurs [26][27][28][29][30][31]. Le métabo-lisme de la caféine a été étudié in vivo et in vitro chez l'Homme et plus d'une dizaine de métabolites urinaires ont été déter-minés par CLHP [31][32][33].…”

Section: Introductionunclassified

Détermination du polymorphisme d’acétylation de la N-acétyltransférase 2 dans la population sénégalaise par utilisation du test à la caféine

Touré¹,

Cabral²,

Diop³

et al. 2012

Ann Toxicol Anal

View full text Add to dashboard Cite

Résumé -Introduction : L'isoniazide (INH) est métabolisée par une N-acétyltransfèrase (NAT), la NAT2. Il existe de nombreux polymorphismes de la NAT2 qui peuvent être associés à des toxicités ou à des échecs thérapeutiques au cours d'un traitement par INH. Objectif : L'objectif de ce travail est de déterminer l'indice d'acétylation de la NAT2 dans la population sénégalaise afin de les répartir en acétyleurs lents et rapides. Méthodes : L'étude du profil d'acétylation a été effectuée sur des urines de 247 sujets en utilisant la caféine comme marqueur. La proportion molaire du 5-acétamino-6-formylamine-3-méthyluracile (AFMU) sur le 1-méthylxanthine (1X) a été déterminée. La répartition de la population étudiée en phénotype lent ou rapide a été réalisée en se basant sur l'antimode = 0,55. Les sujets possédant un rapport ([AFMU]/[1X]) inférieur à 0,55 sont considérés comme des acétyleurs lents et ceux dont le rapport est >0,55 sont des acétyleurs rapides. Résultats : Les résultats obtenus ont montré une ségrégation en deux modes apparents de capacité d'acétylation dans la population sénégalaise testée avec 63,8 % et 36,2 % d'acétyleurs lents et rapides respectivement. Conclusion : La réponse au traitement de maladies comme la tuberculose dépend du polymorphisme d'acétylation de la NAT2, il est donc important de connaître le phénotype de la NAT2 chez les sujets atteints de tuberculose pour éviter des effets indésirables tels que l'hépatotoxicité ou la neurotoxicité. Mots clés : N-acétyltransférase, polymorphisme, indice d'acétylation, test caféineAbstract -Introduction: Isoniazid (INH) is metabolized by an N-acetyltransferase (NAT), the NAT2. There are many of NAT2 polymorphisms that may be associated to toxicity or therapeutic failure of INH. Objective: The objective of this study is to determine the index of acetylation of NAT2 in the Senegalese population. Methods: The study of the profile of acetylation was performed on urine from 247 subjects using caffeine as a marker. The molar ratio of 5-acetamino-6-formyl amine-3-methyluracil (AFMU) on the 1-methylxanthine (IX) was determined. The distribution of the population studied in slow or fast phenotype was performed based on the antimode = 0.55. Subjects who have ratio ([AFMU]/[IX]) less than 0.55 are considered slow acetylators and those, whose ratio is >0.55, are rapid acetylators. Results:The results showed segregation of two apparent modes of acetylation capacity in the Senegalese population tested with 63.8% and 36.2% of slow and fast acetylators respectively. Conclusion: Response to treatment of diseases such as tuberculosis depends on the polymorphism of NAT2 acetylation, it is significant to know the phenotype of NAT2 in patients with tuberculosis to avoid such side effects as hepatotoxicity or neurotoxicity.

show abstract

Human N-acetylation genotype determination with urinary caffeine metabolites

Cited by 39 publications

References 27 publications

A Homogenizing Process of Selection Has Maintained an “Ultra-Slow” Acetylation <em>NAT2</em> Variant in Humans

A Homogenizing Process of Selection Has Maintained an “Ultra-Slow” Acetylation <em>NAT2</em> Variant in Humans

Meat Consumption among Black and White Men and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort

Détermination du polymorphisme d’acétylation de la N-acétyltransférase 2 dans la population sénégalaise par utilisation du test à la caféine

Contact Info

Product

Resources

About